openPR Logo
Press release

Rising Number of Government Pharmacovigilance Centers to Boost Pharmacovigilance Market Growth Worldwide

09-05-2017 08:17 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Rising Number of Government Pharmacovigilance Centers to Boost

Pharmacovigilance is a key component of an effective drug regulation system for monitoring and evaluating adverse drug reactions (ADRs). Pharmacovigilance activities are an important part of clinical research and are growing at a significant pace. At present, the global network of pharmacovigilance centers, harmonized by Uppsala Monitoring Centre, are operating on the global level for appropriate functioning of the process of drug safety monitoring across the world. Large volume of international ADR reports collected in a central database would serve as a contributing factor to the effort of national drug regulatory authorities, thus improving the safety profile of drugs that would help avoid drug related disasters. In addition, growing public health awareness and expectation in relation to the safe use of medicines and medical interventions are some of the major factors contributing to the growth of the global pharmacovigilance market. Furthermore, increasing number of national pharmacovigilance centers globally is playing a definitive role in augmenting public awareness about drug safety, thereby supporting the growth of the pharmacovigilance market in the next few years. However, the pharmacovigilance market is facing several hurdles and challenges to develop a better health care system. Challenges that are acting as major restraining factors for pharmacovigilance market are web-based drug information and sales, perceptions to harm and benefit, high risk associated with data security and unavailability of skilled professionals.

View Full Report:

Based on phases of drug development, the global pharmacovigilance market has been segmented into preclinical studies, clinical trial phase I, II, III and IV or post marketing surveillance. The phase IV or post marketing surveillance segment accounted for the largest share of the pharmacovigilance market in terms of revenue in 2013. Rise in the number of safety concerns pertaining to the marketed product, increasing need for developing systems for comparing safety profiles of similar pharmaceutical products and growth in public health awareness campaigns regarding drug safety issues among the people are the major factors attributed to the high growth of the segment. In addition, the clinical trial phase III segment is expected to grow at the highest CAGR due to the rising need for drug safety monitoring and evaluation in phase III before the drug manufacturer can apply for market authorization application. Additionally, phase III clinical trial focuses on drug safety and efficacy in diverse sub-groups, wherein the risk-benefit ratio is developed, monitored and updated accordingly. Biopharmaceutical companies are in the process of developing advanced clinical trial phases that would be more specific to drug safety. Rigorous pharmacovigilance activities are expected to be made compulsory during the commencement of various clinical trial phases that would be helpful in actively managing high-risk medicines.

Request to view Sample Report:

Based on methods of performing pharmacovigilance, the market has been categorized into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining. Spontaneous reporting method was the largest segment in terms of revenue in 2013. Factors attributed to the growth of the segment are easy simulation of realistic datasets that provides better drug evaluation and comparison, and better assessment of automatic signal generation methods proposed within pharmacovigilance. The segment is also expected to maintain its lead during the forecast period from 2014 to 2020, as in this method, healthcare professionals are encouraged to report adverse reactions after which preventive measures such as adding warnings to the product labeling or recalling the product are taken. Moreover, spontaneous reporting is the most appropriate method of detecting new ADRs and generates safety signals that require further examination.

Based on types of services, the pharmacovigilance market has been segmented into in-house and contract outsourcing. The contract outsourcing service segment accounted for the largest share in 2013. The segment is estimated to grow at the highest CAGR during the forecast period. The major factor driving the growth of the segment is the increasing need of pharmaceutical companies to shift focus from non-core to core business activities by outsourcing their pharmacovigilance services. Moreover, outsourcing of pharmacovigilance services is aimed at minimizing operational cost and financial loss incurred from product approval delays or recalls, thereby propelling the growth of the contract outsourcing service segment.

Request to download and view full ToC -

Geographically, North America accounted for the largest share of the global pharmacovigilance market in 2013. Factors attributed to the growth of the pharmacovigilance market in North America are increasing mortality rate due to ADRs and escalating patient concerns regarding the safety and efficacy of pharmaceutical products. According to the Centers for Disease Control and Prevention (CDC), ADRs account for more than 100,000 deaths annually and are among the top 10 leading causes of death in the U.S. Moreover, cost benefit obtained by shifting high costs of in-house pharmacovigilance activities to CROs is boosting the growth of the market in North America. However, Asia Pacific is anticipated to witness the highest growth during the forecast period. Factors attributed to the high growth are increased demand for stringent health care regulations in Asia, presence of large patient pool and increasing volume of clinical trials being conducted in this region. According to an article published in the National Center for Biotechnology Information in 2014, serious ADRs are witnessed in 6.7% of patients in India. Additionally, demand for effective pharmacovigilance services and drug safety in increasing in the region due to large number of clinical trials and clinical research activities being carried out in various countries in Asia.

The global pharmacovigilance market is fragmented due to the presence of numerous established as well as emerging organizations. The top companies operating in the pharmacovigilance market are Cognizant Technology Solutions, Accenture plc, Bristol-Myers Squibb, Covance, Inc., Clinquest Group B.V., ICON plc, F. Hoffmann-La Roche Ltd., inVentiv Health, Inc., GlaxoSmithKline plc, iGATE Corporation, Novartis International AG, Wipro Limited, Quintiles Transnational Holdings, Inc., Synowledge LLC, Pharmaceutical Product Development, LLC, (PPD), Sanofi, PAREXEL International Corporation, Pfizer, Inc., and iMEDGlobal Corporation.

Global Pharmacovigilance Market Report is available @ US$ 5795:

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rising Number of Government Pharmacovigilance Centers to Boost Pharmacovigilance Market Growth Worldwide here

News-ID: 698014 • Views: 227

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases

More Releases for ADR

Drapery Hardware Market 2022 Advancement And Precise Outlook- IKEA, Rowley Compa …
The Market Insights Reports has added a new statistical market report to its repository titled as, Drapery Hardware Market. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). Furthermore, the report also sheds light on recent developments and technological platforms, in addition to distinctive tools, and methodologies that will help to propel
ADR Wellness Offers Psychotherapy Services for All Ages
CARLSBAD, CA - MAY 7, 2021 - ADR Wellness offers a safe and supportive place for clients as the COVID-19 pandemic continues to impact mental health. The Carlsbad therapy practice owned by Alisa Duclos, PhD, specializes in offering psychotherapy for individuals, couples and families. Its compassionate staff works with clients to develop individual treatment plans that meet clients’ needs. Statistics show that the number of people reporting anxiety and depression has climbed
Investigation announced for Investors in shares of Cheetah Mobile Inc (ADR) (NYS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cheetah Mobile Inc. Investors who are investors in Cheetah Mobile Inc (ADR) (NYSE: CMCM) shares, have certain options and should contact the Shareholders Foundation at or call +1(858) 779 - 1554. The investigation by a law firm for investors in NYSE: CMCM stocks follows a lawsuit filed against Cheetah Mobile Inc over alleged securities
Deadline on August 25, 2020 coming up in Lawsuit for Investors in Cheetah Mobile …
A deadline is coming up on August 25, 2020 in the lawsuit filed for certain investors of Cheetah Mobile Inc (ADR) (NYSE: CMCM) over alleged securities laws violations by Cheetah Mobile Inc. Investors who purchased shares of Cheetah Mobile Inc (ADR) (NYSE: CMCM) have certain options and there are strict and short deadlines running. Deadline: August 25, 2020. NYSE: CMCM stockholders should contact the Shareholders Foundation at or call +1(858)
Lawsuit filed for Investors in shares of Cheetah Mobile Inc (ADR) (NYSE: CMCM)
An investor, who purchased shares of Cheetah Mobile Inc (ADR) (NYSE: CMCM), filed a lawsuit over alleged violations of Federal Securities Laws by Cheetah Mobile Inc in connection with certain allegedly false and misleading statements made between March 25, 2019 and February 20, 2020. Investors, who purchased shares of Cheetah Mobile Inc (ADR) (NYSE: CMCM), have certain options and for certain investors are short and strict deadlines running. Deadline: August 25,
EV Charging Cables Market Detailed Insights on Upcoming Trends 2020-2030 - LEONI …
EV charging cables are the cables that can be plugged straight in a 3-pin socket, available anywhere. These cables are efficiently charge the electric vehicles for the day, possibly even longer. There are several types of sockets that can be plugged with these cables to charge the vehicles, but the major ones include type 1 and type 2. Type 1 is a single-phase socket, having maximum charging speed of 7.4kW.